Revenue: As of FY2025 Q2, the actual value is USD 1.269 M, missing the estimate of USD 1.506 M.EPS: As of FY2025 Q2, the actual value is USD -0.17, missing the estimate of USD -0.1.EBIT: As of FY2025 Q2, the actual value is USD -2.516 M, beating the estimate of USD -2.734 M.<h3>Diagnostic Research and Development (R&amp;D) Segment</h3><ul><li>Net Revenue: $0 for the three months ended June 30, 2025, compared to $4,038 for the same period in 2024. For the six months ended June 30, 2025, net revenue was $0 compared to $6,923 in 2024.</li><li>Operating Expenses: $440,651 for the three months ended June 30, 2025, compared to $453,895 in 2024. For the six months ended June 30, 2025, operating expenses were $946,390 compared to $896,494 in 2024.</li></ul><h3>Laboratory Services Segment</h3><ul><li>Net Revenue: $1,269,483 for the three months ended June 30, 2025, compared to $2,393,614 for the same period in 2024. For the six months ended June 30, 2025, net revenue was $3,123,080 compared to $4,797,120 in 2024.</li><li>Operating Expenses: $1,646,471 for the three months ended June 30, 2025, compared to $2,535,285 in 2024. For the six months ended June 30, 2025, operating expenses were $3,914,127 compared to $5,272,284 in 2024.</li></ul><h3>General Corporate Activities</h3><ul><li>Operating Expenses: $1,697,921 for the three months ended June 30, 2025, compared to $1,496,270 in 2024. For the six months ended June 30, 2025, operating expenses were $3,405,262 compared to $2,668,293 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: -$4,288,981 for the six months ended June 30, 2025, compared to -$3,878,400 in 2024.</li><li>Net Cash Used in Investing Activities: -$64,213 for the six months ended June 30, 2025, compared to -$69,672 in 2024.</li><li>Net Cash Provided by Financing Activities: $4,050,738 for the six months ended June 30, 2025, compared to $1,927,813 in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company aims to expand commercialization of CyPath® Lung as an LDT under CAP/CLIA guidelines and potentially as a CE-marked test in the EU. The company also plans to develop and conduct human clinical studies to support regulatory approval and marketing of its diagnostic tests and therapeutic products.</li><li>Non-Core Business: The company is seeking strategic partners to develop its therapeutic discoveries, which could result in broad-spectrum cancer treatments in the future.</li><li>Priority: The company is focused on raising additional capital through equity or debt securities, strategic relationships, or grants to support its future operations and commercialization efforts.</li></ul>

bioAffinity Tech | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 1.269 M